GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Olink Holding AB (NAS:OLK) » Definitions » Float Percentage Of Total Shares Outstanding

Olink Holding AB (Olink Holding AB) Float Percentage Of Total Shares Outstanding : 33.37% (As of May. 20, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Olink Holding AB Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Olink Holding AB's float shares is 41.49 Mil. Olink Holding AB's total shares outstanding is 124.34 Mil. Olink Holding AB's float percentage of total shares outstanding is 33.37%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Olink Holding AB's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Olink Holding AB's Institutional Ownership is 14.89%.


Olink Holding AB Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Olink Holding AB's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=41.49/124.34
=33.37%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Olink Holding AB (Olink Holding AB) Business Description

Industry
Traded in Other Exchanges
Address
Uppsala Science Park, Uppsala, SWE, SE-75183
Olink Holding AB has a proprietary and patented Proximity Extension Assay technology, which enables researchers to use one platform for discovery to clinical trials to diagnostic applications utilizing the established infrastructure of labs and installed instrumentation. It has two segments including Kit and Services. It derives revenues from Sweden, the Americas, China, EMEA (Excluding Sweden) Japan, and other regions.